DexCom, Inc. DXCM announced that the FDA has approved its G6 Pro Continuous Glucose Monitoring (“CGM”) System for use on patients (aged two years and up). This further fortifies DexCom’s foothold in ...

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM) announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for ...

Dexcom has announced that the US Food and Drug Administration (FDA) has approved its G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients aged 2 ...

When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Tuesday approved the use of a professional continuous glucose monitoring system from Dexcom, ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...